Unspecific *post-mortem* findings despite multiorgan viral spread in COVID-19 patients

3

4	Myriam Remmelink (1), Ricardo De Mendonça (1), Nicky D'Haene (1),
5	Sarah De Clercq (1), Camille Verocq (1), Laetitia Lebrun (1), Philomène Lavis (1),
6	Marie-Lucie Racu (1), Anne-Laure Trépant (1,2), Calliope Maris (1),
7	Sandrine Rorive (1,2), Jean-Christophe Goffard (3), Olivier Dewitte (4),
8	Lorenzo Peluso (7), Jean-Louis Vincent (7), Christine Decaestecker (5,6),
9	Fabio Silvio Taccone (7), Isabelle Salmon (1,2,6)*
10	
11	
12	(1) Department of Pathology, Erasme Hospital, Université Libre de Bruxelles
13	(ULB), Route de Lennik 808, 1070 Brussels, Belgium
14	(2) Centre Universitaire inter Régional d'expertise en Anatomie Pathologique
15	Hospitalière (CurePath, CHIREC, CHU Tivoli, ULB), Rue de Borfilet 12A,
16	6040 Jumet, Belgium
17	(3) Immunodeficiency Treatment Unit, Erasme Hospital, Université Libre de
18	Bruxelles (ULB), Route de Lennik 808, 1070 Brussels, Belgium
19	(4) Department of Neurosurgery, Erasme Hospital, Université Libre de Bruxelles
20	(ULB), Route de Lennik 808, 1070 Brussels, Belgium
21	(5) Laboratory of Image Synthesis and Analysis (LISA), Université Libre de
22	Bruxelles (ULB), CPI 165/57, Avenue Franklin Roosevelt 50, 1050 Brussels,
23	Belgium
24	

24 (6) DIAPath, Center for Microscopy and Molecular Imaging, Université Libre de NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
 25 Bruxelles (ULB), CPI 305/1, Rue Adrienne Bolland, 8, 6041 Gosselies, Belgium

- 26 (7) Department of Intensive Care, Erasme Hospital, Université Libre de Bruxelles
- 27 (ULB), Route de Lennik 808, 1070 Brussels, Belgium
- 28
- 29
- 30
- 31 *Correspondence to: Prof. I. Salmon, Department of Pathology, Erasme Hospital,
- 32 Université Libre de Bruxelles (ULB), Route de Lennik 808, 1070 Brussels, Belgium.
- 33 Isabelle.Salmon@erasme.ulb.ac.be
- 34
- 35

36 Abstract

37 Background

Post-mortem studies can provide important information for understanding new
 diseases and small autopsy case series have already reported different findings in
 COVID-19 patients.

41 *Methods*

We evaluated whether some specific *post-mortem* features are observed in these patients and if these changes are related to the presence of the virus in different organs. Complete macroscopic and microscopic autopsies were performed on different organs in 17 COVID-19 non-survivors. Presence of SARS-CoV-2 was evaluated with immunohistochemistry (IHC) in lung samples and with real-time reverse-transcription polymerase chain reaction (RT-PCR) test in lung and other organs.

49 *Results*

50 Pulmonary findings revealed early-stage diffuse alveolar damage (DAD) in 15 out of 51 17 patients and microthrombi in small lung arteries in 11 patients. Late-stage DAD, 52 atypical pneumocytes and/or acute pneumonia were also observed. Four lung infarcts, 53 two acute myocardial infarctions and one ischemic enteritis were observed. There 54 was no evidence of myocarditis, hepatitis or encephalitis. Kidney evaluation revealed the presence of hemosiderin in tubules or pigmented casts in most patients. 55 56 Spongiosis and vascular congestion were the most frequently encountered brain 57 lesions. No specific SARS-CoV-2 lesions were observed in any organ. IHC revealed 58 positive cells with a heterogeneous distribution in the lungs of 11 of the 17 (65%) 59 patients; RT-PCR yielded a wide distribution of SARS-CoV-2 in different tissues, 60 with 8 patients showing viral presence in all tested organs (i.e. lung, heart, spleen, 61 liver, colon, kidney and brain).

62 *Conclusions*

- 63 In conclusion, autopsies revealed a great heterogeneity of COVID-19-related organ
- 64 injury and the remarkable absence of any specific viral lesions, even when RT-PCR
- 65 identified the presence of the virus in many organs.
- 66
- 67 Keywords
- 68 COVID-19, SARS-CoV-2, autopsy, RT-PCR, immunohistochemistry
- 69

71 Background

72 Coronaviruses, including severe acute respiratory syndrome coronavirus (SARS-73 CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV), cause severe 74 acute respiratory failure, which is associated with high mortality rates (1). The novel 75 SARS-CoV-2 strain exhibits phylogenetic similarities to SARS-CoV and causes 76 coronavirus disease 2019 (COVID-19), which has caused more than 280,000 deaths 77 worldwide so far. As the pandemic has progressed, the pathophysiology of this viral 78 infection has become clearer; in particular, it has been shown that SARS-CoV-2 can 79 directly alter cell function by a link to the angiotensin converting enzyme 2 (ACE2) 80 receptor, which is almost ubiquitous in the human body (2).

Nevertheless, the mechanisms behind the high mortality and severe organ dysfunction associated with COVID-19 remain poorly understood. Controversies exist regarding the occurrence of fatal complications, such as pulmonary embolism or diffuse endothelial injury (3, 4), as well as on the roles of direct viral cellular injury or concomitant comorbidities in the fatality of this disease (5).

In this setting, autopsy is of great importance to help physicians understand the biological characteristics and the pathogenesis of COVID-19. Most of the previously reported *post-mortem* findings focused on lung morphology and few data are available on complete *post-mortem* analyses of other organs (6, 7). The aim of this study was therefore to investigate the presence of specific features of viral injury as well as the distribution of the virus in different organs of patients who died from COVID-19.

93

95 Methods

96 Study design

97 In this *post-mortem* study, we included the first 17 adult patients (>18 years) who 98 died in our hospital (either in a COVID-19 unit or an intensive care unit) from March 99 13, 2020 with confirmed SARS-CoV-2 infection (i.e. positive RT-PCR assay on 100 nasopharyngeal swab and/or broncho-alveolar lavage specimen). Autopsies were 101 performed 72 to 96 hours after death to ensure the safety of the autopsy team. 102 Exclusion criteria were lack of family consent and a delay of more than five days 103 after death. The study protocol was approved by the local ethics committee 104 (P2020/218).

105

106 Data collection

We collected demographics, comorbidities, relevant clinical data, the results of chest computed tomography scan, and if available, microbiological tests and medical treatments (e.g. hydroxychloroquine, antivirals or antibiotics, and use of organ support). Acute respiratory distress syndrome (ARDS) and acute kidney injury (AKI) were defined according to standard definitions (8, 9).

112

113 *Post-mortem procedure*

The Belgian Sciensano guidelines were integrated into our *post-mortem* procedure (10). Personal protective equipment consisted of two superposed disposable latex gloves, plastic sleeves, FFP3 mask, scrub hat, clear face visor, surgical gown plus plastic apron, rubber boots. In the *post-mortem* room, dirty and clean circulations were used in the airlocks to allow decontamination. For 11 cases, brain samples were obtained using a safety procedure with drills and protective devices to avoid air dispersion, as described in the Additional file 1 (Additional Material).

121 Using standard surgical pathology processing, complete sets of tissue samples were 122 collected for diagnosis and biobanking. The material was biobanked by Biobanque 123 Hôpital Erasme-ULB (BE_BERA1), CUB Hôpital Erasme; BBMRI-ERIC. The 124 banked material consists of 6 samples per organ, including trachea, thyroid, lymph 125 nodes, heart, spleen, bone marrow, kidney, bladder, liver, stomach, colon, and brain. 126 For the lungs, we collected six samples per lobe (i.e. a total of 30 samples), except for 127 two patients who had undergone lobectomy for cancer and from whom only 18 128 samples were taken. For safety reasons, complete brain removal was not allowed, but, 129 with the help of a neurosurgeon, we developed a new procedure to obtain between 12 130 and 51 samples from different brain regions, as detailed in the Additional file 1 131 (Additional Material). Formalin-fixed paraffin-embedded (FFPE) tissues underwent 132 standard processing to provide hematoxylin and eosin (H&E)-stained sections. 133 Special stains and immunohistochemistry (IHC) were used for lung (Masson's 134 trichrome, periodic acid-Schiff [PAS], Gomori-Grocott, anti-CMV IHC, anti-HSV 135 IHC, anti-Pneumocystis J IHC) and kidney (PAS, Masson's trichrome, Jones 136 methenamine silver) samples.

137

138 Morphological analysis

Morphological analysis was performed on H&E stained glass slides using the
SecundOs digital platform (TribVn Health Care, Chatillon, France) for digital
diagnosis, after acquisition of whole slide digital scans (40x magnification) using a
Nanozoomer 2.0 HT slide scanner (Hamamatsu, Hamamatsu City, Japan).

143

144 SARS-CoV-2 detection by immunohistochemistry

145 Since no antibody against SARS-CoV-2 has been validated for IHC on FFPE tissues,

146 we selected an anti-SARS-nucleocapsid protein antibody. Standard IHC was applied

147 as previously described to 4-µm-thick *post-mortem* lung sections (one sample for 148 each lung lobe per patient) to display SARS-nucleocapsid protein (Invitrogen, PA1-41098, dilution 1:50) on Dako Omnis (Agilent Technologies, Santa Clara, CA, USA) 149 150 using the Envision Flex detection system according to the manufacturer's protocol 151 (11). The sections were counterstained with hematoxylin. Negative tissue controls 152 were obtained from patients who had an autopsy before the COVID-19 pandemic. 153 Semi-quantitative IHC evaluation was performed by two senior pathologists (ND, 154 MR) as follows: negative (-); between one and five positive cells per whole slide 155 (scattered cells, +); more than five cells per whole slide but no foci (isolated cells, 156 ++); and with foci (more than 10 cells in one 20X field, +++).

157

158 SARS-CoV-2 detection by rRT-PCR

Total nucleic acid was extracted from FFPE tissues using the Maxwell RSC DNA 159 160 FFPE Kit (reference: AS1450. Promega Corporation, Madison, WI, USA) and the 161 Promega Maxwell extractor, following the protocol described by the manufacturer. One-step RT-PCR assays specific for the amplification of SARS-CoV-2 E envelope 162 163 protein gene were adapted from a published protocol (12). Briefly, 4 µL of RNA (100 164 ng) was amplified in 20 µL reaction mixture containing 5 µL of TaqMan Fast Virus 165 master mix (Life Technologies), 0.4 uМ each forward 1-step of 166 (ACAGGTACGTTAATAGTTAATAGCGT) and reverse (ATATTGCAGCAGTACGCACACA) primers and 0.2 µM of probe (FAM-167 ACACTAGCCATCCTTACTGCGCTTCG-BBQ). The amplification condition was 168 169 50°C for 10 min for reverse transcription, followed by 95°C for 20 seconds and then 170 45 cycles of 95°C for 3 seconds and 58°C for 30 seconds. A clinical sample highly 171 positive for SARS-CoV-2 was diluted 1:1000 and used as a positive control in each 172 analysis. A clinical sample obtained from a patient who was autopsied before the

173	COVID-19 pandemic was used as a negative control. The quality of the RNA from
174	the samples showing negative results was assessed by amplification of the human
175	MET RNA according to a validated ISO:15189 accredited method used as a routine
176	diagnostic method in our laboratory.
177	

178 Statistical analysis

179 Data are reported as counts (percentage) or medians [interquartile ranges (IQRs)]. All

180 data were analyzed using GraphPad Prism Version 8.4.2 (GraphPad Software, San

181 Diego, CA, USA).

182

184 Study cohort

185 The main characteristics of the study cohort (12 males out of 17; median age 72 [62-77] years) are given in Table 1. The median time from admission to death was 13 [8-186 187 15] days. All except two patients had at least one comorbidity, including hypertension (n=10), diabetes (n=9), cerebrovascular disease (n=4), coronary artery 188 189 disease (n=4) and solid cancer (n=4). None of the patients had tested positive on admission for the Respiratory Syncytial Virus or influenza A and B viruses. Eleven 190 191 patients died in the ICU and 6 on the medical ward; the main causes of death were respiratory failure (n=9) and multiple organ failure (n=7). Laboratory data are 192 193 reported in Additional file 2 (Table S1).

194

195 Macroscopic Findings

One patient had had a left pneumonectomy and one patient a right bilobectomy. The lungs were typically heavy and the lung parenchyma had a diffuse firm consistency with red/tan and patchy dark/red areas of hemorrhage. Thrombi were found in the

199 large pulmonary arteries in 2 patients and lung infarction in 4 patients. Pleural 200 adhesions associated with pleural effusions were observed in 4 cases. We observed cardiomegaly in 14 and and hepatomegaly in 5 patients. The kidneys were often 201 202 enlarged, with a pale cortex and petechial aspect but no hemorrhage or infarct. The 203 gut had advanced *post-mortem* autolysis with no evidence of specific lesions, except 204 for one patient who had ischemic enteritis. In the 11 patients for whom brain samples 205 were available, one had had a recently drained subdural hematoma and another had a 206 cerebral hemorrhage.

207

208 Microscopic Findings

209 As shown in Figures 1 and 2 and Additional file 3 (Table S2), the main pulmonary 210 findings included early-stage diffuse alveolar damage (DAD), which consisted of 211 interstitial and intra-alveolar edema, with variable amounts of hemorrhage and fibrin deposition, hyaline membranes, minimal interstitial mononuclear inflammatory 212 213 infiltrate and type II pneumocyte hyperplasia. Microthrombi were noted in the small 214 pulmonary arteries in 11 patients. Ten of the 17 patients also had advanced DAD 215 lesions (i.e. fibroblastic proliferation within the interstitium and in the alveolar 216 spaces); 8 patients had evidence of acute pneumonia or broncho-pneumonia, 4 had 217 atypical pneumocytes and three syncytial multinucleated giant cells. We observed no 218 viral inclusions or squamous metaplasia.

Fifteen patients had signs of chronic ischemic cardiomyopathy of different severities and 2 patients had signs of acute myocardial infarction; there was no evidence of contraction bands or myocarditis. Histological evaluation of the kidneys was limited because of moderate to severe *post-mortem* autolysis; occasional hemosiderin granules were observed in the tubular epithelium in 9 patients and pigmented casts in 12. In the medulla, edematous expansion of the interstitial space without significant

inflammation was observed in 4 patients. Chronic renal lesions (i.e. nodular
mesangial expansion and arteriolar hyalinosis, glomerulosclerosis or chronic
pyelonephritis) were also observed; no microthrombi were identified, but one patient
had a thrombus in an interlobar artery.

Liver examination revealed congestive hepatopathy and steatosis, but no patchy necrosis, hepatitis or lobular lymphocytic infiltrate. The histological changes in the abdominal organs including the esophagus, stomach and colon are reported in Additional file 3 (Table S2); most of the findings were related to chronic underlying diseases, except for one case of ischemic enteritis.

Brain samples showed cerebral hemorrhage or hemorrhagic suffusion (n=8), focal ischemic necrosis (n=3), edema and/or vascular congestion (n=5), and diffuse or focal spongiosis (n=10). We found no evidence of viral encephalitis or vasculitis, isolated neuronal necrosis or perivascular lymphocytic infiltration.

238

239 SARS-CoV-2 detection in the lungs by IHC

240 SARS-CoV-2 was identified by IHC in the lungs of 11 of the 17 patients (Figure 3).

However, there was large variability in the distribution of SARS-CoV-2 positive cells
in the lung parenchyma.

243

244 SARS-CoV-2 detection by RT-PCR

245 SARS-CoV-2 RNA was detected in at least one organ from every patient (Figure 4).

In the lung, RT-PCR was positive in 16 patients, with threshold cycle (Ct) values

varying from 16.02 to 33.03. Viral RNA was also detected in the heart (n=14), the

liver (n=14), the bowel (n=14), the spleen (n=11), and the kidney (n=10) as well as in

9 of the 11 cerebral samples. Ct values for non-pulmonary organs ranged from 28.67

to 35.11. Eight patients had positive RT-PCR in all tested organs.

251

252 Discussion

253 This post-mortem study showed several histopathological abnormalities in COVID-

19 non-survivors; however, none of the findings was specific for direct viral injury.

Moreover, the distribution of the infected cells was heterogeneous within the lung parenchyma. Finally, using RT-PCR, the virus could be detected in all examined organs.

258 The diagnosis of SARS-CoV-2-related organ injury is challenging; post-mortem 259 histological findings were heterogeneous and often associated with chronic 260 underlying diseases. In a previous autopsy study in COVID-19 patients (3), the 261 authors reported that DAD associated with viral pneumonia was almost impossible to 262 distinguish from that caused by bacterial pneumonia. No obvious intranuclear or 263 intracytoplasmic viral inclusions were identified in another report (6). Desquamation 264 of pneumocytes and hyaline membrane formation are frequently described in ARDS 265 of many different causes, especially in early-phase ARDS (13). The presence of 266 multinucleated cells with nuclear atypia is used to diagnose herpes virus infection in 267 daily practice. As in previous reports (6, 14), we also observed the presence of 268 multinucleated cells within lung alveoli in three patients; however, the significance of 269 multinucleated cells is unclear and may not be specific of SARS-CoV-2 infection 270 (15). Finally, some of the microscopic features of these patients are compatible with 271 organ changes secondary to shock or systemic inflammation and no histological 272 finding could be specifically ascribed to SARS-CoV-2.

273 In the absence of typical *post-mortem* viral features, our results show that RT-PCR is 274 feasible on FFPE blocks and could be used in *post-mortem* analyses to identify the 275 presence of SARS-CoV-2 in multiple organs and to understand the spread of the 276 virus within the human body. The discordant RT-PCR and IHC results for detection 277 of SARS-CoV2 in the lungs may be explained by the different sensitivity of these 278 assays, which was higher for the RT-PCR, whereas low-level viral replication might 279 not be detected by IHC. Moreover, IHC was based on the only available antibodies, 280 which are targeted against SARS-CoV. New antibodies against SARS-CoV-2 need to 281 be developed to improve the accuracy of IHC in the analysis of tissue samples from 282 suspected or confirmed COVID-19 patients.

Most of the previous post-mortem studies in COVID-19 patients were conducted 283 284 using needle biopsies and were therefore rather limited in terms of sampling; our 285 complete autopsy analysis identified considerable heterogeneity of SARS-CoV-2 286 spread through the human body, and provides a more accurate description of 287 macroscopic and microscopic organ alterations. As for previous coronavirus diseases 288 (16, 17), the lungs are the most affected organs in COVID-19. However, DAD 289 findings were highly heterogeneous, including both early-onset and additional late 290 lesions. This finding could be explained by the heterogeneity of the pulmonary 291 injury, including compliant lungs in the early phase and a more dense and non-292 recruitable lung in the late phase (18). As some patients died outside the ICU without 293 undergoing mechanical ventilation, we could not estimate lung compliance before 294 death. The heterogeneity could also reflect different treatments (e.g. fluid 295 administration or corticosteroids) or different complications; as an example, half of 296 the patients had concomitant acute pneumonia and it is difficult to conclude whether the DAD reflected the natural time-course of the viral disease or was secondary to 297 298 superimposed complications, such as nosocomial infections. In a recent report, needle

299 post-mortem biopsies suggested that COVID-19 is not associated with DAD but 300 rather with an acute fibrinous and organizing pneumonia (AFOP), consequently requiring corticoid treatment (19). A diagnosis of AFOP is based on the absence of 301 302 hyaline membranes and the presence of alveolar fibrin balls; however, hyaline 303 membranes are heterogeneously distributed in the lung parenchyma with DAD and 304 complete lung analysis, not just biopsies, are necessary to exclude their presence. 305 Moreover, AFOP may be a fibrinous variant of DAD (20). The limitation of lung 306 biopsy was also shown in another study, in which only 50% of lung samples were 307 positive for SARS-CoV-2 using RT-PCR (21), when compared to almost 100% in our series. In addition, we did not find specific "endothelitis" as previously reported 308 309 in a small case series (4). Considering the heterogeneity of post-mortem COVID-19 associated lesions, molecular and IHC assessment are mandatory in the histological 310 311 analysis of COVID-19 tissue samples.

312 Patients with COVID-19 often have altered coagulation and a prothrombotic status, 313 with the possible development of acute pulmonary embolism (PE) (22). In our study, 314 three patients had PE, already diagnosed before death. Four patients had pulmonary 315 infarction. In a previous study, acute PE was considered as the main cause of death in 316 four patients (3); however, the inclusion of patients who died before hospital 317 admission and the lack of specific thromboprophylaxis during the hospital stay may 318 account for the differences in the severity of PE when compared to our study. 319 Although we frequently observed the presence of microthrombi in the lung 320 parenchyma, this feature is also reported in other forms of ARDS, regardless of 321 etiology (13, 23). As such, whether diffuse pulmonary thrombosis is a main 322 contributor of the fatal course of severe hypoxemia in COVID-19 patients remains to 323 be further studied.

324 We did not observe specific viral organ injury, such as myocarditis, hepatitis or encephalitis. The cases of "acute cardiac injury" reported in COVID-19 clinical 325 326 studies (24), do not necessarily translate into myocarditis or acute myocardial 327 ischemia (only two had acute myocardial ischemia), similar to data reported in septic 328 patients (i.e. elevated troponin without overt cardiac ischemia) (25). However, using 329 RT-PCR, we found the virus in almost all the examined organs; this suggests that the 330 virus can link to most cells, probably via the ACE2 receptor, which is ubiquitous, but 331 may not directly cause organ injury. As extra-pulmonary direct viral injury (e.g. 332 encephalitis, hepatitis, or myocarditis) has only been reported in very few cases, we 333 suggest that SARS-CoV-2 infection may be just the trigger for an overwhelming host 334 response, which could secondarily result in COVID-19-associated organ dysfunction. 335 As RT-PCR might just detect residual viral genome, it remains unclear whether this 336 represents active viral replication into the tissues or previous cellular infection, 337 without clinically relevant significance (26).

338 This study has several limitations. First, the sample size was relatively small, and 339 autopsies were only carried out from 72 to 96 hours after death. This delay did not 340 allow us to properly analyze the gastrointestinal tract and kidneys, which showed 341 signs of autolysis; in particular, acute tubular injury in the proximal tubules was 342 indistinguishable from autolysis. Second, we could not determine the time-course 343 and/or sequence of organ spread of the virus and no specific hypothesis regarding 344 how SARS-CoV-2 spread (e.g. hematogenously) could be identified. Third, the time 345 to death differed from patient to patient as did the course of the disease and 346 treatments received, which limits a precise clinical-pathological correlation of 347 histological findings related to COVID-19. Finally, we did not evaluate specific mechanisms involved in the pathogenesis of organ injury. 348

350 Conclusion

- 351 These results underline the heterogeneity of organ injuries during COVID-19 disease
- and the absence of specific SARS-CoV-2 lesions. Using RT-PCR, SARS-CoV-2
- 353 could be detected in all organs, even those without evident microscopic lesions.

354

355 List of abbreviations

- 356 ACE2: angiotensin converting enzyme 2
- 357 AFOP: acute fibrinous and organizing pneumonia
- 358 AKI: acute kidney injury
- 359 ARDS: Acute respiratory distress syndrome
- 360 COVID-19: coronavirus disease 2019
- 361 Ct: threshold cycle
- 362 DAD: diffuse alveolar damage
- 363 FFPE: Formalin-fixed paraffin-embedded
- 364 H&E: hematoxylin and eosin
- 365 IHC: immunohistochemistry
- 366 IQRs: interquartile ranges
- 367 MERS-CoV: Middle East respiratory syndrome coronavirus
- 368 PAS: periodic acid-Schiff
- 369 PE: pulmonary embolism
- 370 RT-PCR: real-time reverse-transcription polymerase chain reaction
- 371 SARS-CoV: severe acute respiratory syndrome coronavirus

372 Declarations

373 *Ethics approval*

The study protocol was approved by the local ethics committee (Erasme Hospital P2020/218). The ethical committee has waived the need for written informed consent.

377

- 378 Consent for publication
- Not applicable

380

381 Availability of data and materials

382 The data that support the findings of this study are available from the corresponding 383 author on reasonable request. Participant data without names and identifiers will be 384 made available after approval from the corresponding author and local Ethics 385 Committee. The research team will provide an email address for communication once 386 the data are approved to be shared with others. The proposal with detailed description of study objectives and statistical analysis plan will be needed for evaluation of the 387 388 reasonability to request for our data. Additional materials may also be required 389 during the process.

390

391 *Competing interests*

392 The authors declare that they have no competing interests.

393

394 Funding

This study received financial support from Fonds Y. Boël (Brussels, Belgium), Fonds
Erasme pour la Recherche Médicale (Brussels, Belgium), and "Appel à projet Spécial
COVID-19 - ULB" (Brussels, Belgium). The CMMI is supported by the European

398	Regional Develo	pment Fund and th	e Walloon F	Region of I	Belgium (Wallonia-biomed:

- grant no. 411132-957270; project "CMMI-ULB" support the Center for Microscopy
- 400 and Molecular Imaging and its DIAPath department). CD is a Senior Research
- 401 Associate with the F.N.R.S. (Belgian National Fund for Scientific Research).
- 402
- 403 Authors' contributions
- 404 IS had the idea for and designed the study and had full access to all the data in the
- study and takes responsibility for the integrity of the data and the accuracy of the data
- 406 analysis.
- 407 IS, FT, JLV, and CD drafted the paper.
- 408 MR, CV, LL, PL, MLR, CM, ALT, JCG, LP, RDM, SD, SR, ND, LP, OD collected 409 the data.
- 410 MR, ND, RDM did the analysis, and all authors critically revised the manuscript for
- 411 important intellectual content and gave final approval for the version to be published.
- 412 All authors agree to be accountable for all aspects of the work in ensuring that
- 413 questions related to the accuracy or integrity of any part of the work are appropriately
- 414 investigated and resolved.
- 415

416 Acknowledgments

The authors thank Nathalie Lijsen, Christophe Valleys, Barbara Alexiou, Dominique Penninck, Nicole Haye and Audrey Verrellen for technical and logistic supports, Prof Frédéric Schuind for neurosurgical procedure, Egor Zindy (DIAPath, ULB) for proofreading the paper and Dr Marie-Paule Van Craynest for trainees' supervision.

- 421
- 422

423 **References**

424	1.	Guan WJ	. Ni ZY.	Hu Y.	Liang W	VH. Ou CO). He JX	. et al.	Clinical	Characteristics
		0.0000000000000000000000000000000000000	, ,				<,	.,	01111000	011011010100100

- 425 of Coronavirus Disease 2019 in China. N Engl J Med. 2020;382:1708-20
- 426 2. Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et
- 427 al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a
- 428 clinically proven protease inhibitor. Cell. 2020;181:1-10.
- 429 3. Wichmann D, Sperhake JP, Lütgehetmann M, Steurer S, Edler C, Heinemann A,
- 430 et al. Autopsy Findings and Venous Thromboembolism in Patients With COVID-
- 431 19: A Prospective Cohort Study. Ann Intern Med. 2020. Epub ahead of print. doi:
 432 10.7326/M20-2003
- 4. Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R, Zinkernagel AS,
 et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020;
 395:1417-8.
- 5. Chen T, Wu D, Chen H, Yan W, Yang D, Chen G, et al. Clinical characteristics
 of 113 deceased patients with coronavirus disease 2019: retrospective study.
 BMJ. 2020. Epub ahead of print. doi: 10.1136/bmj.m1091
- Ku Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, et al. Pathological findings of
 COVID-19 associated with acute respiratory distress syndrome. Lancet Respir
 Med. 2020;8:420-2.
- 442 7. Barton LM, Duval EJ, Stroberg E, Ghosh S, Mukhopadhyay S. COVID-19
 443 autopsies, Oklahoma, USA. Am J Clin Pathol. 2020;153:725-33.
- 8. ARDS Definition Task Force, Ranieri VM, Rubenfeld GD, Thompson BT,
 Ferguson ND, Caldwell E, Fan E, et al. Acute respiratory distress syndrome: the
 Berlin Definition. JAMA. 2012;307:2526-33.

447 9. Kellum JA, Lameire N; KDIGO AKI Guideline Work Group.	447	. Diagnosis
--	-----	-------------

448 evaluation, and management of acute kidney injury: a KDIGO summary (Part 1).

449 Crit Care. 2013;17:204.

- 450 10. Procédure pour les hôpitaux: prise en charge d'un patient possible ou confirmé
- 451 COVID-19.https://epidemio.wiv-isp.be/ID/Documents/Covid19/COVID-
- 452 <u>19_procedure_deaths_FR.pdf</u>. Accessed 03/16/20.
- 453 11. D'Haene N, Meléndez B, Blanchard O, De Nève N, Lebrun L, Van Campenhout
- C, et al. Design and Validation of a Gene-Targeted, Next-Generation Sequencing
 Panel for Routine Diagnosis in Gliomas. Cancers (Basel). 2019;11:773.
- 456 12. Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DK, et al.
- 457 Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro
 458 Surveill. 2020;25: 2000045.
- 459 13. de Hemptinne Q, Remmelink M, Brimioulle S, Salmon I, Vincent JL. ARDS: a
 460 clinicopathological confrontation. Chest. 2009;135: 944-9.
- 461 14. Menter T, Haslbauer JD, Nienhold R, Savic S, Hopfer H, Deigendesch N, et al.
- 462 Post-mortem examination of COVID19 patients reveals diffuse alveolar damage
- with severe capillary congestion and variegated findings of lungs and other
 organs suggesting vascular dysfunction. Histopathology. 2020. Epub ahead of
 print. doi: 10.1111/his.14134.
- 466 15. Franks TJ, Chong PY, Chui P, Galvin JR, Lourens RM, Reid AH, et al. Lung
 467 pathology of severe acute respiratory syndrome (SARS): a study of 8 autopsy
 468 cases from Singapore. Hum Pathol. 2003;34:743-8.
- 469 16. Nicholls JM, Poon LL, Lee KC, Ng WF, Lai ST, Leung CY, et al. Lung
 470 pathology of fatal severe acute respiratory syndrome. Lancet. 2003;361:1773-8.

471	17. Hwang, D., Chamberlain, D., Poutanen, S. Low DE, Asa SL, Butany J.
472	Pulmonary pathology of severe acute respiratory syndrome in Toronto. Mod
473	Pathol. 2005;18:1-10.
171	18 Cattinoni I. Chiumallo D. Bossi S. COVID 10 proumonio: APDS or not ? Crit

- 474 18. Gattinoni L, Chiumello D, Rossi S. COVID-19 pneumonia: ARDS or not ? Crit
 475 Care. 2020;24:154.
- 476 19. Copin MC, Parmentier E, Duburcq, T Poissy J, Mathieu D and The Lille COVID-
- IQU and Anatomopathology Group. Time to consider histologic pattern of
 lung injury to treat critically ill patients with COVID-19 infection. Intensive Care
 Med. 2020 Apr 23:1–3.
- 20. Santos C, Oliveira RC, Serra P, Baptista JP, Sousa E, Casanova P, et al.
 Pathophysiology of acute fibrinous and organizing pneumonia Clinical and
 morphological spectra. Pathophysiology. 2019; 26:213-7.
- 483 21. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of
 484 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in
 485 Wuhan, China. JAMA. 2020. Epub ahead of print. doi: 10.1001/jama.2020.1585.
- 486 22. Llitjos JF, Leclerc M, Chochois C, Monsallier JM, Ramakers M, Auvray M, et al.
- High incidence of venous thromboembolic events in anticoagulated severe
 COVID-19 patients. J Thromb Haemost. 2020. Epub ahead of print. doi:
 10.1111/jth.14869.
- 23. Chang JC. Acute Respiratory Distress Syndrome as an Organ Phenotype of
 Vascular Microthrombotic Disease: Based on Hemostatic Theory and Endothelial
 Molecular Pathogenesis. Clin Appl Thromb Hemost.
 2019;25:1076029619887437.
- 494 24. Shi S, Qin M, Shen B, Cai Y, Liu T, Yang F, et al. Association of cardiac injury
 495 with mortality in hospitalized patients with COVID-19 in Wuhan, China. JAMA
 496 Cardiol. 2020. Epub ahead of print. doi: 10.1001/jamacardio.2020.0950.

- 497 25. Smeding L, Plötz FB, Groeneveld AB, Kneyber MC. Structural changes of the
- 498 heart during severe sepsis or septic shock. Shock. 2012;37:449-56.
- 499 26. Wölfel R, Corman VM, Guggemos W, Seilmaier M, Zange S, Müller MA, et al.
- 500 Virological assessment of hospitalized patients with COVID-2019. Nature. 2020.
- 501 Epub ahead of print. doi: 10.1038/s41586-020-2196-x.
- 502
- 503
- 504
- 505
- 506

507 Legends to Figures

- 508 Figure 1: Main histological findings. Green = finding present; Gray = finding absent;
 509 Black = unavailable.
- 510

Figure 2: Pulmonary histological findings. A) Early stage diffuse alveolar damage
(DAD): hyaline membrane (H&E, 50x magnification) with a zoom on a giant cell
(100x magnification). B) Fibrin thrombi in a pulmonary artery (H&E, 50x
magnification). C) Late stage DAD: fibroblastic proliferation (H&E, 50x
magnification). D) Late stage DAD: fibroblastic proliferation (Trichrome staining,
50x magnification). E) Acute pneumonia (H&E, 50x magnification). F) Anti-SARSCoV immunohistochemistry (IHC)-positive cells (200x magnification)

518

Figure 3: Detection of SARS-CoV-2 by immunohistochemistry (IHC) in FFPE *post- mortem* lung samples of 17 patients. Semi-quantitative evaluation: "-"negative result;
"+": scattered positive cells (between 1 and <5 positive cells/whole slide); "++":
positive isolated cells (> 5 cells/whole slide, but no foci); "+++": foci of positive cells
(more than 10 positive cells in one 200x field); NA = not available.

524

Figure 4: Molecular detection of SARS-Cov-2 RNA in *post-mortem* samples. Detection of SARS-CoV-2 by reverse transcription real-time polymerase chain reaction (RT-PCR) in FFPE *post-mortem* tissues of 17 patients. "+" positive result; "-"negative result; "NA" tissue not available, NC: non-informative test result (due to low quality RNA).

530

 Table 1: Characteristics of the study population.

ID	Age	Sex	Comorbidities	CT- scan	rRT- PCR	Time to	Ante-mortem	Treatments	Cause of death
						death	Organ Failure		
1	77	М	CAD	NEG	POS	3	ARDS	Mechanical ventilation	Cardiogenic shock
			CVD				AKI	Antibiotics	MOF
			Diabetes						
2	91	F	Hypertension	NEG	POS	15	ARDS	Hydroxychloroquine	Respiratory failure
			CAD				AKI	Antibiotics	
			CRF				Hypoxic hepatitis	Corticosteroids	
			Liver cirrhosis						
3	68	М	COPD	GGO	POS	15	ARDS	Mechanical ventilation	Respiratory failure
			Cancer				AKI	Hydroxychloroquine	

								Lopinavir/Ritonavir Antibiotics	
4	64	F	Hypertension Cancer CVD	MA	POS	8	ARDS	Mechanical ventilation Hydroxychloroquine Antibiotics	Respiratory failure
5	56	Μ	COPD Cancer	GGO	POS	14	ARDS AKI Hypoxic hepatitis	Mechanical ventilation ECMO RRT Hydroxychloroquine Lopinavir/Ritonavir Antibiotics	Mesenteric ischemia MOF
6	73	М	Hypertension CRF	BC	POS	11	ARDS AKI	Mechanical ventilation ECMO	Respiratory failure

								Hydroxychloroquine Remdesivir Corticosteroids Antiobiotics	
7	56	М	None	BC	POS	7	ARDS	Hydroxychloroquine	Respiratory failure
							AKI	Antibiotics	
							Hypoxic hepatitis		
8	66	М	Hypertension	Emphysema	POS	14	AKI	Antibiotics	Septic shock
			CAD						MOF
			CVD						
			CRF						
			Diabetes						

9	49	F	Hypertension	GGO	POS	17	ARDS	Mechanical ventilation	Respiratory failure
			Diabetes				AKI	RRT	
								Hydroxychloroquine	
								Lopinavir/Ritonavir	
								Antibiotics	
10	63	М	Hypertension	GGO	POS	16	ARDS	Mechanical ventilation	Respiratory failure
			Diabetes	BC			AKI	ECMO	
								RRT	
								Hydroxychloroquine	
								Oseltamivir	
								Antibiotics	
11	76	М	Diabetes	BC	POS	5	ARDS	Hydroxychloroquine	Sudden death
			Liver cirrhosis					Antibiotics	

			Cancer Diabetes						
12	75	М	Hypertension CAD Diabetes	GGO	POS	6	ARDS AKI Hypoxic hepatitis	Mechanical ventilation Hydroxychloroquine Antibiotics	MOF
13	73	М	Diabetes	GGO BC	POS	10	ARDS	Hydroxychloroquine	Respiratory failure
14	77	F	Hypertension Diabetes	GGO BC	POS	9	ARDS AKI Hypoxic hepatitis	Hydroxychloroquine Antibiotics	Respiratory failure
15	61	М		GGO	POS	31	ARDS	Mechanical ventilation	Septic shock

				LP			AKI	RRT	MOF
							Pulmonary embolism	Hydroxychloroquine	
								Remdesivir	
								Antibiotics	
16	70	F	Hypertension	GGO	POS	19	ARDS	Mechanical ventilation	Septic shock
			Diabetes	BC			AKI	RRT	MOF
			Liver transplant				Pulmonary embolism	Hydroxychloroquine	
								Antibiotics	
17	53	М	Hypertension	GGO	POS	13	ARDS	Mechanical ventilation	Septic shock
			CVD	BC			AKI	ECMO	MOF
				LP			Pulmonary embolism	RRT	
								Hydroxychloroquine	
								Antibiotics	

Time to death = time from admission to death (days). Cause of death was reported by the attending physician. M = male; F = female; rRT-PCR = reverse transcription real-time polymerase chain reaction used as diagnostic laboratory test; NEG = negative; POS = positive; CAD = coronary artery disease; CVD = cerebrovascular disease; LP = lobar pneumonia; GGO = ground-glass opacity; MA = minor abnormalities; BC = bilateral consolidation; COPD = chronic obstructive pulmonary disease; CRF = chronic renal failure; ARDS = acute respiratory distress syndrome; AKI = acute kidney injury; ECMO = extracorporeal membrane oxygenation; RRT = renal replacement therapy; MOF = multiple organ failure.

Additional files:

Additional file 1:

Critical care-autopsy-Covid-Additional file 1.doc

Additional material

Procedure to obtain brain samples

Additional file 2:

Critical care-autopsy-Covid-Additional file 2.doc

Additional table S1

Laboratory findings on the day of admission

Additional file 3:

Critical care-autopsy-Covid-Additional file 3.doc

Additional table S2

Detailed histological findings in all patients

Early Diffuse Alveolar Damage Lung Microthrombosis Lung infarct Acute (broncho)-pneumonia

Ischemic Cardiomyopathy Acute myocardial infarction Cardiac Fibrosis

Congestive Hepatopathy Liver Cirrhosis Hepatic Steatosis

Hemosiderin renal tubules Pigmented renal casts


Bone Marrow Hyperplasia Ischemic enteritis

medRxiv preprint doi: https://doi.org/10.1101/2020.05.27.20114363; this version posted May 28, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

> Cerebral Focal Necrosis Cerebral Hemorrhage Cerebral Oedema Cerebral Spongiosis

1	2	3	4	5	6	7	8	9	10	111	12	13	14	15	16	17

			Ĩ					




RIGHT SUPERIOR

1	
2	
3	
5	
6	
8	
9	
10	
12	
13	
https://doi.org/10.1101/2020.05.27.20114363 May 2. vright ho dv a lide the prepr ermiss	
15	
16	
17	







RIGHT



LUNG LOBES









2		
3		
5		
6		
8		
9		
10		
11		
12		
13		
https://doi.org/10.1101/2020.05.27.20114363 sver wi) is the constant of the	for this preprint perpetuity.	
15		
16		
17		







HEART	SPLEEN	LIVER	KIDNEY	BOWEL	BRAIN
<image/>					
		NC			NA
					NA
					NA
					NA
					NA
					NA
	NC				

